For research use only. Not for therapeutic Use.
HDAC6-IN-23 (compound 9) is an orally active HDAC6 inhibitor[1].
Catalog Number | I040282 |
CAS Number | 2991427-09-7 |
Synonyms | 2-(difluoromethyl)-5-[6-[(5-pyridin-2-yltetrazol-2-yl)methyl]pyridin-3-yl]-1,3,4-oxadiazole |
Molecular Formula | C15H10F2N8O |
Purity | ≥95% |
InChI | InChI=1S/C15H10F2N8O/c16-12(17)15-22-21-14(26-15)9-4-5-10(19-7-9)8-25-23-13(20-24-25)11-3-1-2-6-18-11/h1-7,12H,8H2 |
InChIKey | ZTVLPDLCENUSAG-UHFFFAOYSA-N |
SMILES | C1=CC=NC(=C1)C2=NN(N=N2)CC3=NC=C(C=C3)C4=NN=C(O4)C(F)F |
Reference | [1]. Ripa L, et al. Selective and Bioavailable HDAC6 2-(Difluoromethyl)-1,3,4-oxadiazole Substrate Inhibitors and Modeling of Their Bioactivation Mechanism [published online ahead of print, 2023 Oct 5]. J Med Chem. 2023;10.1021/acs.jmedchem.3c01269. |